Neuroinflammation Unit, Biotech Research and Innovation Centre, University of Copenhagen, Denmark.
J Clin Invest. 2011 Jan;121(1):249-64. doi: 10.1172/JCI43964. Epub 2010 Dec 13.
NKT cells in the mouse recognize antigen in the context of the MHC class I-like molecule CD1d and play an important role in peripheral tolerance and protection against autoimmune and other diseases. NKT cells are usually activated by CD1d-presented lipid antigens. However, peptide recognition in the context of CD1 has also been documented, although no self-peptide ligands have been reported to date. Here, we have identified an endogenous peptide that is presented by CD1d to activate mouse NKT cells. This peptide, the immunodominant epitope from mouse collagen type II (mCII707-721), was not associated with either MHC class I or II. Activation of CD1d-restricted mCII707-721-specific NKT cells was induced via TCR signaling and classical costimulation. In addition, mCII707-721-specific NKT cells induced T cell death through Fas/FasL, in an IL-17A-independent fashion. Moreover, mCII707-721-specific NKT cells suppressed a range of in vivo inflammatory conditions, including delayed-type hypersensitivity, antigen-induced airway inflammation, collagen-induced arthritis, and EAE, which were all ameliorated by mCII707-721 vaccination. The findings presented here offer new insight into the intrinsic roles of NKT cells in health and disease. Given the results, endogenous collagen peptide activators of NKT cells may offer promise as novel therapeutics in tissue-specific autoimmune and inflammatory diseases.
NKT 细胞在小鼠中识别 MHC Ⅰ类样分子 CD1d 所呈递的抗原,并在周围耐受和预防自身免疫和其他疾病中发挥重要作用。NKT 细胞通常被 CD1d 呈递的脂质抗原激活。然而,已经记录了在 CD1 背景下的肽识别,尽管迄今为止尚未报道任何自身肽配体。在这里,我们已经鉴定出一种由 CD1d 呈递以激活小鼠 NKT 细胞的内源性肽。这种肽,即来自小鼠胶原 II 型(mCII707-721)的免疫优势表位,与 MHC Ⅰ类或Ⅱ类均无关联。通过 TCR 信号和经典共刺激诱导 CD1d 限制性 mCII707-721 特异性 NKT 细胞的激活。此外,mCII707-721 特异性 NKT 细胞通过 Fas/FasL 诱导 T 细胞死亡,方式不依赖于 IL-17A。此外,mCII707-721 特异性 NKT 细胞抑制多种体内炎症状态,包括迟发型超敏反应、抗原诱导的气道炎症、胶原诱导的关节炎和 EAE,所有这些状态均通过 mCII707-721 疫苗接种得到改善。本研究结果为 NKT 细胞在健康和疾病中的内在作用提供了新的见解。鉴于这些结果,内源性胶原肽激活剂可能为组织特异性自身免疫和炎症性疾病的新型治疗方法提供希望。